K-gli Tablet
Glimepiride
1 mg
Blue Cross Laboratories Pvt. Ltd.
| Pack size | 1 |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 1.68 NPR |
Available as:
Indications
K-gli Tablet is used for:
Type 2 DM
Adult Dose
Oral
Type 2 diabetes mellitus
Adult: Initially, 1-2 mg daily. May be increased in increments of 1-2 mg at intervals of 1-2 wk. Maintenance: 4 mg daily. Max: 6 mg daily.
Elderly: Initially, 1 mg once daily.
Hepatic impairment: Severe: Contraindicated.
Child Dose
Safety and efficacy not established
Renal Dose
Renal impairment: 1 mg PO qDay; titrate dose based on fasting blood glucose levels
Severe: Contraindicated.
Administration
Should be taken with food. Take immediately before or during breakfast, or the 1st main meal of the day. Do not skip meals.
Contra Indications
Diabetic ketoacidosis with or without coma.
Precautions
Increased risk of CV mortality. Elderly; hepatic and renal impairment. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in patients with CHF or hepatic cirrhosis. Monitor blood-glucose concentration. Pregnancy, lactation.
Lactation: Excretion in milk unknown; avoid
Pregnancy-Lactation
Interactions
Salicylates, sulfonamides, chloramphenicol, clarithromycin, coumarin anticoagulants, probenecid, CYP2C9 inhibitors, fibric acid derivatives, disopyramide, fluoxetine, quinolones, ACE inhibitors, MAOIs and ?-blockers may potentiate the hypoglycaemic action of glimepiride. Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, oestrogens, phenytoin, nicotinic acid, sympathomimetics and CYP2C9 inducers may reduce hypoglycaemic effect of glimepiride. Reduced plasma concentration w/ colesevelam.
Adverse Effects
Side effects of Glimepiride :
>10%
Hypoglycemia (4-20%)
1-10%
Dizziness (1.7%),Asthenia (1.6%),Headache (1.5%),Nausea (1.1%)
<1%
Allergic skin reactions,Erythema,Morbilliform or maculopapular eruptions,Pruritus,Urticaria,Diarrhea,Gastrointestinal pain,Vomiting,Agranulocytosis,Anemia,Aplastic anemia,Leukopenia,Pancytopenia,Thrombocytopenia, hemolytic,Cholestasis,Elevation of liver enzyme levels,Hepatic porphyria reactions,Jaundice (rare),Disulfiram-like reactions,Hyponatremia
Mechanism of Action
Glimepiride stimulates the insulin release from pancreatic ?-cells and reduces glucose output from the liver. It also increases insulin sensitivity at peripheral target sites.
Note
K-gli 1 mg Tablet manufactured by Blue Cross Laboratories Pvt. Ltd.. Its generic name is Glimepiride. K-gli is availble in Nepal.
Farmaco Nepal drug index information on K-gli Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.